BiotechTube

Escitalopram

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Anxiety Disorders,Generalized Anxiety Disorder

Conditions

Anxiety Disorders,Generalized Anxiety Disorder

Trial Timeline

May 30, 2019 → Sep 20, 2021

NCT ID
NCT03924323

About Escitalopram

Escitalopram is a approved stage product being developed by AbbVie for Anxiety Disorders,Generalized Anxiety Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03924323. Target conditions include Anxiety Disorders,Generalized Anxiety Disorder.

What happened to similar drugs?

18 of 20 similar drugs in Anxiety Disorders,Generalized Anxiety Disorder were approved

Approved (18) Terminated (2) Active (2)
✅Duloxetine + PlaceboEli LillyApproved
✅Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved
✅Cariprazine + PlaceboAbbVieApproved
✅QuetiapineAstraZenecaApproved
✅Quetiapine extended release tablet + PlaceboAstraZenecaApproved
✅QuetiapineAstraZenecaApproved
✅Alprazolam (Xanax) + PlaceboRocheApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03924323ApprovedCompleted

Competing Products

20 competing products in Anxiety Disorders,Generalized Anxiety Disorder

See all competitors
ProductCompanyStageHype Score
Duloxetine + venlafaxine + placeboEli LillyPhase 3
40
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
39
Duloxetine + PlaceboEli LillyPhase 3
40
duloxetine hydrochloride + placeboEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyApproved
43
Duloxetine Hydrochloride + placeboEli LillyPhase 3
40
duloxetine + placeboEli LillyPhase 3
40
Duloxetine + venlafaxine + placeboEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
eszopiclone + eszopiclone + PlaceboSumitomo PharmaPhase 2
35
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved
43
risperidone oral tabletsJohnson & JohnsonPhase 3
40
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)AbbViePhase 2
42
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/dayAbbViePhase 2
27
ABBV-932 + PlaceboAbbViePhase 1
29
Cariprazine + PlaceboAbbVieApproved
43
QuetiapineAstraZenecaApproved
43
Quetiapine extended release tablet + PlaceboAstraZenecaApproved
43
AZD7325 + Radioligand (11C) flumazenilAstraZenecaPhase 1
29
AZD7325 + AZD7325 + AZD7325 + PlaceboAstraZenecaPhase 2
35